SOPHiA GENETICS SA

SOPH Healthcare Health Information Services

SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue grew 27.2%, EPS grew 9.88%, free cash flow grew 6.50% and total debt rose 1.12%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

6.73 0.56 −7.68%
Market cap
$620.6M
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
2/9
Altman Z
−3.43
Beneish M
−3.30
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
4.94 4.34 4.08 4.40
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(55.39) (23.29) (38.77) (36.70)
P/B ratio
5.13 7.71 6.69 5.32
EV/Sales
4.27 4.14 3.81 3.96
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(8.91) (8.04) (8.04) (7.44)
Current Ratio
2.69 2.06 1.96 2.80
Net Debt/EBITDA
3.48 1.21 1.40 2.20
Debt/Equity
0.58 1.05 1.01 0.78
Earnings Yield
(19.93%) (23.90%) (25.12%) (23.59%)
Free Cash Flow Yield
(9.69%) (11.87%) (11.61%) (12.10%)
Free Cash Flow per Share
(0.11) (0.23) (0.12) (0.13)
Book value per Share
1.13 0.64 0.70 0.90
Free Cash Flow
(7.84) (16.03) (8.36) (9.03)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates